Edgewise Therapeutics Draws Takeover Interest After Strategic Pivot to Cardiovascular Focus
Reports of a potential sale process lifted Edgewise Therapeutics (EWTX) shares, with multiple pharmaceutical companies said to be involved.
Reports of a potential sale process lifted Edgewise Therapeutics (EWTX) shares, with multiple pharmaceutical companies said to be involved.
Report cites competition and prior 95% decline after 2021 peak.
The non-binding bid values the rare obesity drugmaker at up to $134 a share.
Usona’s potential FDA filing for psilocybin makes the competitive landscape more real for Compass, Definium, Helus Pharma and GH Research, analyst says.
Oric shares declined after Johnson & Johnson reported a 75% tumor response rate with JNJ-6143 in heavily pretreated advanced prostate cancer patients.
HealthSpan Partners will acquire Surgery Partners for $23.50 per share in a $5.7B deal. Bain Capital rolls its stake. Close expected Q1 2027.